HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of the GluK1/AMPA receptor antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.

Abstract
Control of brain seizures after exposure to nerve agents is imperative for the prevention of brain damage and death. Animal models of nerve agent exposure make use of pretreatments, or medication administered within 1 minute after exposure, in order to prevent rapid death from peripheral toxic effects and respiratory failure, which then allows the testing of anticonvulsant compounds. However, in a real-case scenario of an unexpected attack with nerve agents, pretreatment would not be possible, and medical assistance may not be available immediately. To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)/α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman. We injected LY293558 intramuscularly, as this would be the most likely route of administration to humans. LY293558 (15 mg/kg), injected along with atropine and the oxime HI-6 at 20 minutes after soman exposure, stopped seizures and increased survival rate from 64% to 100%. LY293558 also prevented neuronal loss in the amygdala and hippocampus, and reduced neurodegeneration in a number of brain regions studied 7 days after soman exposure. Analysis of the LY293558 pharmacokinetics after intramuscular administration showed that this compound readily crosses the blood-brain barrier. There was good correspondence between the time course of seizure suppression by LY293558 and the brain levels of the compound.
AuthorsJames P Apland, Vassiliki Aroniadou-Anderjaska, Taiza H Figueiredo, Carol E Green, Robert Swezey, Chun Yang, Felicia Qashu, Maria F M Braga
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 344 Issue 1 Pg. 133-40 (Jan 2013) ISSN: 1521-0103 [Electronic] United States
PMID23042954 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Anticonvulsants
  • Antidotes
  • Cholinesterase Inhibitors
  • Fluoresceins
  • Fluorescent Dyes
  • Gluk1 kainate receptor
  • Isoquinolines
  • Muscarinic Antagonists
  • Oximes
  • Pyridinium Compounds
  • Receptors, AMPA
  • Receptors, Kainic Acid
  • Tetrazoles
  • fluoro-jade C
  • tezampanel
  • Atropine
  • Soman
  • asoxime chloride
Topics
  • Animals
  • Anticonvulsants
  • Antidotes
  • Atropine (therapeutic use)
  • Brain (metabolism)
  • Cholinesterase Inhibitors (poisoning)
  • Electroencephalography (drug effects)
  • Fluoresceins
  • Fluorescent Dyes
  • Injections, Intramuscular
  • Isoquinolines (administration & dosage, pharmacokinetics, pharmacology)
  • Male
  • Muscarinic Antagonists (pharmacology)
  • Nerve Degeneration (pathology)
  • Oximes (pharmacology)
  • Pyridinium Compounds (pharmacology)
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, AMPA (antagonists & inhibitors)
  • Receptors, Kainic Acid (antagonists & inhibitors)
  • Seizures (drug therapy, physiopathology)
  • Soman (antagonists & inhibitors, poisoning)
  • Tetrazoles (administration & dosage, pharmacokinetics, pharmacology)
  • Tissue Fixation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: